0001209191-21-069050.txt : 20211210 0001209191-21-069050.hdr.sgml : 20211210 20211210163250 ACCESSION NUMBER: 0001209191-21-069050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210831 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Menzel Garry E CENTRAL INDEX KEY: 0001556064 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 211485805 MAIL ADDRESS: STREET 1: C/O REGULUS THERAPEUTICS INC. STREET 2: 3545 JOHN HOPKINS COURT SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-31 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001556064 Menzel Garry E C/O TCR2 THERAPEUTICS 100 BINNEY STREET CAMBRIDGE MA 02142 1 1 0 0 President & CEO Common Stock 84527 I See Footnote Common Stock 2021-08-31 5 A 0 E 422 14.26 A 4507 D Common Stock 2021-12-09 4 M 0 175000 0.74 A 179507 D Stock Option (Right to Buy) 0.74 2021-12-10 4 M 0 169054 0.74 A 2026-12-12 Common Stock 169054 0 D Stock Option (Right to Buy) 0.74 2021-12-10 4 M 0 5946 0.74 A 2027-12-06 Common Stock 5946 138031 D Stock Option (Right to Buy) 5.21 2021-12-09 4 A 0 305800 0.00 A 2031-12-08 Common Stock 305800 305800 D Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021. The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. 25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter /s/ Margaret Siegel as Attorney-in-Fact 2021-12-10